Pluri Inc. is a biotechnology company operating through its Israeli subsidiary Pluri Biotech Ltd. and related entities. The company develops cell-based technologies across regenerative medicine, immunotherapy, food technology, and agriculture technology (AgTech). Key products include PLX-PAD and PLX-R18 placenta-expanded cell therapies. Pluri also operates a Contract Development and Manufacturing Organization (CDMO) business leveraging its mass-scale, cost-effective cell expansion platform.
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-17 | 2025-06-30 | 0001213900-25-088578 | EDGAR | 67K words |
| 2024-09-18 | 2024-06-30 | 0001213900-24-079861 | EDGAR | — |
| 2023-09-12 | 2023-06-30 | 0001213900-23-076079 | EDGAR | — |
| 2022-09-21 | 2022-06-30 | 0001213900-22-057677 | EDGAR | — |
| 2021-09-13 | 2021-06-30 | 0001213900-21-047664 | EDGAR | — |
| 2020-09-10 | 2020-06-30 | 0001213900-20-026105 | EDGAR | — |
| 2019-09-12 | 2019-06-30 | 0001213900-19-017859 | EDGAR | — |
| 2018-09-12 | 2018-06-30 | 0001178913-18-002512 | EDGAR | — |
| 2017-09-07 | 2017-06-30 | 0001178913-17-002643 | EDGAR | — |
| 2016-09-07 | 2016-06-30 | 0001178913-16-006442 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001213900-26-015550 | EDGAR | 20K words |
| 2025-11-12 | 2025-09-30 | 0001213900-25-109174 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001213900-25-042637 | EDGAR | — |
| 2025-02-11 | 2024-12-31 | 0001213900-25-012189 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001213900-24-096763 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001213900-24-041274 | EDGAR | — |
| 2024-02-12 | 2023-12-31 | 0001213900-24-012549 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001213900-23-086065 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001213900-23-037682 | EDGAR | — |
| 2023-02-13 | 2022-12-31 | 0001213900-23-010734 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001213900-22-071138 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001213900-22-024864 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001213900-26-035110 | EDGAR | 18K words |
| 2026-03-02 | 0001213900-26-022025 | EDGAR | — |
| 2026-01-22 | 0001213900-26-006685 | EDGAR | — |
| 2025-12-09 | 0001213900-25-119651 | EDGAR | — |
| 2025-10-16 | 0001213900-25-099632 | EDGAR | — |
| 2025-09-12 | 0001213900-25-087052 | EDGAR | — |
| 2025-09-11 | 0001213900-25-086670 | EDGAR | — |
| 2025-07-03 | 0001213900-25-061364 | EDGAR | — |
| 2025-05-27 | 0001213900-25-047562 | EDGAR | — |
| 2025-05-08 | 0001213900-25-040816 | EDGAR | — |
367 total filings indexed. 335 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001158780 |
| Ticker | PLUR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | NV |
| Website | https://www.pluri-biotech.com |
| Listed | 1991-10-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report